Late cardiotoxicity in patients with malignant lymphoma treated with doxorubicin chemotherapy

Česká verzia

Authors: L. Elbl ¹; I. Vášová ²; M. Navrátil ²; I. Tomášková ¹; F. Jedlička ¹; V. Chaloupka ¹; J. Vorlíček ²
Authors place of work: Oddělení funkčního vyšetřování FN Brno, pracoviště Bohunice, přednosta doc. MUDr. Václav Chaloupka, CSc. ¹; Interní hematoonkologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jiří Vorlíček, CSc. ²
Published in the journal: Vnitř Lék 2006; 52(4): 328-338
Category: Original Contributions

Summary

Aim of the study:
Chronic cardiotoxicity of doxorubicin occurs at least one year after the chemotherapy is finished. As such, it is a serious late complication in patients with malignant lymphomas. The aim of the study was to identify the incidence of late clinical and subclinical doxorubicin cardiotoxicity and cardiopulmonary performance of patients being in remission for five and more years from the initial therapy.

Group of patients:
We worked with 96 patients (47 men and 49 women) aged 43 ± 15 (median 41, 23–79) years. Average period of monitoring was 6.2 ± 1.5 (median 6.5–10) years. On the basis of therapy protocol, the patients were administered a maximum doxorubicin cumulative dose (CD DOX) of 377 ± 147 (median 300, 50–880) mg/m2. Additional treatment after initial conventional therapy was performed in 32 patients (33%) due to high risk, progression or relapse of tumour.

Examination methods:
Patients were examined by resting echocardiography before and after initial therapy, and during follow-up examination after 5 years. Also, dynamic stress echocardiography and spiroergometry were performed during follow-up examination. Left ventricle ejection fraction (LVEF) decrease below 50 %, progressive decrease of LVEF > 10 % as compared with initial value, and decreased peak oxygen intake pVO2 < 20 ml/kg/min were considered as pathological. We also evaluated systolic function and index of myocardial performance (Tei-index).

Results:
Clinical cardiotoxicity was observed in 4 % of patients, subclinical in 31 % of patients. Diastolic dysfunction was found in 38 % of patients; pathological values of Tei-index were noted in 31 % of patients. Value of stress increment of LVEF was 13 ± 4 % (median 12; 5–25). Decreased pVO2 was observed in 15 % of patients. Cardiovascular disease and age > 60 years represent a higher risk of left ventricular dysfunction. Additional treatment after initial therapy represents a higher risk only if diastolic dysfunction is found (OR = 2.37, p < 0.05). Multi-dimensional regression analysis proved the relationship between pathological EF, CD DOX ≥ 300 mg/m2, age > 60 years and cardiovascular disease (for CD DOX p < 0.05; age p < 0.01; concomitant cardiovascular disease p < 0.01, with r = 0.57 and p < 0.02 values for the overall model).

Conclusions:
The above-mentioned findings should positively influence the approach of oncologists and haematologists to long-term cardiological monitoring (at least with the help of resting echocardiography) in adult patients treated with antracyclines during initial chemotherapy.

Key words:
late cardiotoxicity – malignant lymphomas – doxorubicin – echocardiography

Zdroje

1. Diehl V, Thomas RT, Re D. Hodgkin’s lymphoma-diagnosis and treatment. Lancet 2004; 5: 19-26.

2. Messori A, Vaiani M, Trippoli S. Survival in patients with intermediate or high-grade non-Hodgkin’s lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP. Br J Cancer 2001; 84: 303-307.

3. Lefrak EA, Pitha J, Rosenheim S et al. A clinicopathologic analysis of Adriamycin cardiotoxicity. Cancer 1973; 32: 302-314.

4. Lipshultz SE, Colan SD, Gelber RD et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324: 808-815.

5. Steinherz LJ, Steinherz PG, Tan CTC et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266: 1672-1677.

6. Elbl L, Hrstkova H, Chaloupka V. The late consequences of anthracycline treatment on left ventricular function after treatment for childhood cancer. Eur J Pediatr 2003; 162: 690-696.

7. Elbl L, Hrstkova H, Tomaskova I et al. Long-term serial echocardiographic examination of late cardiotoxicity and its prevention by dexrazoxane in paediatric patients. Eur J Pediatr 2005; 164: 678-684.

8. Hequet O, Le QH, Moullet I et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 2004; 22: 1864-1871.

9. Ryberg M, Nielsen D, Skovsgaard T et al. Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer. J Clin Oncol 1998; 16: 3502-3508.

10. Anderlini P, Benjamin RS, Wong FC et al. Idarubicin cardiotoxicity: A retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol 1995; 13: 2827-2834.

11. Aviles A, Arevila A, Diaz Maqueo JC et al. Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin’s disease in adults. Leuk Lymphoma 1993; 11: 275-279.

12. Otto CM. Echocardiographic evaluation of left and right ventricular systolic function. In: Otto CM Textbook of clinical echocardiography. 2nd ed. Philadelphia: WB Saunders 2000: 100-131.

13. Tei Ch, Ling LH, Hodge DO et al. New index of combined systolic and diastolic myocardial performance: A simple and reproducible measure of cardiac function - a study in normals and dilated cardiomyopathy. J Cardiol 1995; 26: 357-366.

14. Moller LE, Egstrup K, Kober L et al. Prognostic importance of systolic and diastolic function after acute myocardial infarction. Am Heart J 2003; 145: 147-153.

15. Szymanski P, Rezler J, Stec S et al. Long-term prognostic value of an index of myocardial performance in patients with myocardial infarction. Clin Cardiol 2002; 25: 378-383.

16. Chaloupka V, Elbl L. Zátěžová echokardiografie. Praha: Maxdorf 1997.

17. Beck KC, Weisman IM. Methods for cardiopulmonary exercise testing. In: Weisman IM, Zeballos RJ (eds). Clinical exercise testing. Prog Respir Res. Basel, Karger; 2002, 43-59.

18. Quigg RJ. Clinical utility of cardiopulmonary exercise testing data in heart failure. In: Balady GJ, Pina IL. Exercise and heart failure. New York: Futura Publishing Company, Inc. Armonk 1997: 221-243.

19. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-717.

20. Shan K, Lincoff M, Young J. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996; 125: 47-58.

21. Singal P, Iliskovic N. Current concepts: doxorubicin-induced cardiomyopathy. N Engl J Med 1998; 339: 900-905.

22. Friedman MA, Bozdech MJ, Billingham ME et al. Doxorubicin cardiotoxicity: Serial endomyocardial biopsies and systolic time intervals. JAMA 1978; 240: 1603-1606.

23. Simbre VC, Duffy SA, Dadlani GH et al. Cardiotoxicity of cancer chemotherapy. Implication for children. Pediatr Drugs 2005; 7: 187-202.

24. Nair R, Ramakrishnan G, Nair NN et al. A randomized comparison of the efficacy and toxicity of epirubicin and doxorubicin in the treatment of patients with non-Hodgkin’s lymphoma. Cancer 1998; 82: 2282-2288.

25. Limat S, Demesmay K, Viollat L et al. Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin’s lymphoma. Ann Oncol 2003; 14: 277-281.

26. Young JB. The prognosis of heart failure. In: Mann DL. Heart Failure. Philadelphia: Elsevier Inc 2004.

27. Suzuki J, Yanagisawa A, Shigeyana T et al. Early detection of anthraycline-induced cardiotoxicity by radionuclide angiography. J Vasc Diseases 1999; 50: 37-45.

28. Brown KA, Blow AJ, Weiss RM et al. Acute effects of doxorubicin on human left ventricular systolic and diastolic function. Am Heart J 1989; 118: 979-982.

29. Cassidy SC, Chan DP, Rowland DG et al. Effects of doxorubicin on diastolic function, contractile reserve, and ventricular-vascular coupling in piglets. Pediatr Cardiol 1998; 19: 450-457.

30. Boucek RJ. Mechanismus for anthracycline-induced cardiomyopathy: clinical and laboratory correlations. Progress Pediatr Cardiol 1998; 8: 59-70.

31. Harjai KJ, Scott L, Vivekananthan K et al. The Tei index: A new prognostic index for patients with symptomatic heart failure. J Am Soc Echocardiogr 2002; 15: 864-868.

32. Bruch C, Schmermund A, Marin D et al. Tei-index in patients with mild-to-moderate congestive heart failure. Eur Heart J 2000; 21: 1888-1895.

33. Ocal B, Oguz D, Karademir S et al. Myocardial performance index combining systolic and diastolic myocardial performance in doxorubicin-treated patients and its correlation to conventional Echo/Doppler indices. Pediatr Cardiol 2002; 23: 522-527.

34. Chanan-Cahn A, Srinivasan S, Czuczman MS. Prevention and management of cardiotoxicity from antineoplastic therapy. J Support Oncol 2004; 2: 251-266.

35. Youssef G, Links M. The prevention and management of cardiovascular complications of chemotherapy in patients with cancer. Am J Cardiovasc Drugs 2005; 5: 233-234.

36. Bejnamin EJ, Levy D, Keaven M et al. Determinants of Doppler indexes of left ventricular diastolic function in normal subjects (the Framingham Heart Study). Am J Cardiol 1992; 70: 508-515.

37. Hanckock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin’s disease in children and adolescents. J Clin Oncol 1993; 11: 1208-1215.

38. Elbl L, Vasova I, Tomaskova I et al. Cardiopulmonary exercise testing in the evaluation of functional capacity after treatment of lymphomas in adults. Leukemia&Lymphoma 2006; 47: 1-9.